Plain-English guide for Kentucky parents about newborn jaundice, bilirubin monitoring, phototherapy, and prevention of kernicterus.
Updated August 2026
Jaundice is extremely common in newborns.
Most cases are mild and resolve without causing injury.
The danger occurs when unconjugated bilirubin rises to a level that can enter the brain and cause bilirubin toxicity.
The acute condition is called acute bilirubin encephalopathy.
The permanent neurological consequences of bilirubin toxicity are called kernicterus.
Because severe hyperbilirubinemia is treatable, preventing bilirubin-related brain injury depends on a reliable system:
measure → compare with the correct threshold → identify risk → treat when indicated → recheck → escalate before bilirubin reaches dangerous levels.
For babies born at 35 weeks’ gestation or later, the current U.S. standard clinical framework is the American Academy of Pediatrics’ 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia.
As of August 2026, the AAP identifies this as its current guideline and states that it remains valid for clinical use through August 2027.
Jaundice Is Common. Kernicterus Is Not.
Bilirubin forms as red blood cells break down.
A newborn’s liver then has to process bilirubin so the body can eliminate it.
During the first days after birth, bilirubin often rises because:
- Newborns have a relatively high red-blood-cell mass
- Those cells turn over quickly
- The newborn liver is still maturing
- Feeding and stooling are still being established
That is why many healthy newborns become somewhat yellow.
The problem is not simply:
“Is the baby jaundiced?”
The important questions are:
What is the bilirubin level?
How old is the baby in hours?
What is the baby’s gestational age?
How quickly is bilirubin rising?
Are neurotoxicity risk factors present?
How close is the level to treatment or exchange-transfusion thresholds?
The AAP notes that more than 80% of newborns develop some degree of jaundice, while severe bilirubin toxicity is uncommon when appropriate monitoring and treatment occur.
What Is Acute Bilirubin Encephalopathy?
Acute bilirubin encephalopathy refers to the neurological effects of bilirubin toxicity during the newborn period.
Possible signs can include:
- Poor feeding
- Lethargy
- Difficulty waking
- Abnormal muscle tone
- High-pitched cry
- Arching of the neck or back
- Retrocollis
- Opisthotonus
- Recurrent apnea
These signs can represent a medical emergency.
The AAP recommends an urgent exchange transfusion when a jaundiced newborn shows intermediate or advanced signs of acute bilirubin encephalopathy, even apart from the numerical bilirubin threshold.
What Is Kernicterus?
Kernicterus refers to the chronic and permanent neurological consequences of bilirubin toxicity.
Possible long-term effects include:
- Movement disorders
- Choreoathetoid cerebral palsy
- Abnormal muscle tone
- Sensorineural hearing loss
- Auditory neuropathy
- Upward-gaze abnormalities
- Dental enamel abnormalities
- Characteristic brain MRI findings
It is therefore useful to distinguish:
Acute bilirubin encephalopathy = the acute neurological syndrome
from:
Kernicterus = chronic permanent bilirubin-related neurological injury
That distinction is more precise than using “kernicterus” for every stage of bilirubin toxicity.
Good Bilirubin Monitoring Starts Before the Baby Looks Severely Yellow
Visual examination is useful.
It is not enough by itself.
The AAP recommends that newborns be visually assessed for jaundice at least every 12 hours after delivery until discharge.
If jaundice is seen during the first 24 hours, a transcutaneous bilirubin or serum bilirubin should be obtained as soon as possible because early jaundice raises concern for processes such as hemolysis.
But visual examination does not replace objective bilirubin measurement.
Studies reviewed by the AAP have found differences of 13–15 mg/dL between visually estimated and actually measured bilirubin in some cases.
Every newborn should therefore have at least one objective bilirubin measurement before discharge.
When Should Every Newborn Have a Bilirubin Measurement?
For babies covered by the AAP guideline, the recommendation is straightforward:
A TcB or TSB should be measured between 24 and 48 hours after birth—or before discharge if the baby is discharged earlier.
This applies even when the baby does not look severely jaundiced.
The AAP’s July 2025 implementation FAQ reiterates that all newborns should have a bilirubin level measured at least once before discharge and that follow-up should be guided by that result.
TcB vs. TSB: What’s the Difference?
Parents may see two abbreviations:
TcB — Transcutaneous Bilirubin
A TcB device estimates bilirubin by measuring light reflected from the baby’s skin.
It is useful for screening.
TSB — Total Serum Bilirubin
A TSB is measured from a blood sample.
The AAP states that TSB is the definitive test used to make treatment decisions, including decisions about:
- Phototherapy
- Escalation of care
- Exchange transfusion
A TcB can tell clinicians when a blood measurement should be obtained.
But treatment decisions should ultimately be based on serum bilirubin when the level is near a treatment threshold.
When Should a TcB Be Confirmed With a Blood Test?
Under the AAP guideline, a TSB should be obtained if the TcB:
- Is within 3 mg/dL of the phototherapy threshold
- Exceeds the phototherapy threshold
- Is 15 mg/dL or higher
This is an important safety rule.
A TcB of “14” does not mean the same thing for every newborn.
The clinician has to know:
- Baby’s age in hours
- Gestational age
- Applicable phototherapy threshold
- Relevant neurotoxicity risks
before deciding whether serum confirmation is required.
Bilirubin Is Not Interpreted Using One Universal Number
There is no single bilirubin level at which every newborn should receive phototherapy.
The correct threshold changes according to:
- Gestational age
- Baby’s age in hours
- Presence of bilirubin neurotoxicity risk factors
That is why a bilirubin of 16 mg/dL might be managed differently in:
- A 36-week infant at 30 hours
- A healthy 40-week infant at 96 hours
- A baby with hemolysis
- A baby with sepsis
- A clinically unstable NICU patient
The number must always be placed on the appropriate hour-specific treatment curve.
Which Babies Are at Higher Risk?
There are actually two different kinds of risk clinicians consider.
That distinction is important.
Risk Factors for Developing Significant Hyperbilirubinemia
These help predict which babies are more likely to develop a high bilirubin.
Examples include:
- Lower gestational age
- Jaundice during the first 24 hours
- Predischarge bilirubin close to the phototherapy threshold
- Known or suspected hemolysis
- Rapid bilirubin rise
- Phototherapy during the birth hospitalization
- Parent or sibling who required phototherapy or exchange transfusion
- Family history suggesting an inherited red-cell disorder
- Exclusive breastfeeding with suboptimal intake
- Significant bruising or scalp hematoma
- Other clinical circumstances identified by the AAP
These factors may justify closer surveillance.
Neurotoxicity Risk Factors Are Different
Hyperbilirubinemia neurotoxicity risk factors affect how susceptible the baby may be to bilirubin-related neurological injury and therefore lower treatment thresholds.
The AAP identifies:
- Gestational age below 38 weeks, with risk increasing with greater prematurity
- Albumin below 3.0 g/dL
- Isoimmune hemolytic disease
- G6PD deficiency
- Other hemolytic conditions
- Sepsis
- Significant clinical instability during the previous 24 hours
One nuance is important:
For babies born at 35 through 37 6/7 weeks, gestational age is already incorporated into the gestational-age-specific treatment curves.
The AAP FAQ states that the lower-threshold figure for babies with additional neurotoxicity risks should not automatically be used merely because a baby was born before 38 weeks. An additional neurotoxicity risk factor is needed.
Why Hemolysis Matters
Hemolysis means red blood cells are breaking down unusually quickly.
That can make bilirubin rise rapidly.
Possible causes include:
- Rh incompatibility
- ABO incompatibility with clinically significant hemolysis
- Other maternal antibodies
- G6PD deficiency
- Other red-cell disorders
A baby with hemolysis may move toward treatment thresholds much more quickly than a baby with ordinary physiologic jaundice.
How Fast Is “Too Fast” for Bilirubin to Rise?
When more than one bilirubin measurement is available, the rate of rise can provide a clue.
The AAP describes the following as unusually rapid and suggestive of hemolysis:
First 24 hours:
at least 0.3 mg/dL per hour
After 24 hours:
at least 0.2 mg/dL per hour
A rapid rise does not independently diagnose the cause.
It should prompt additional evaluation for hemolysis or another source of excessive bilirubin production.
Why G6PD Deficiency Deserves Special Attention
Glucose-6-phosphate dehydrogenase deficiency, or G6PD deficiency, is an inherited condition that can cause sudden red-blood-cell breakdown.
The AAP identifies G6PD deficiency as an important cause of severe hyperbilirubinemia and kernicterus.
It can be especially difficult because:
- There may be little warning
- Bilirubin can rise rapidly
- Family history may be absent
- The first test can occasionally be misleading during or shortly after a hemolytic event
The 2024 AAP phototherapy technical report recommends G6PD testing when jaundice has no clear cause and bilirubin:
- Rises despite intensive phototherapy
- Suddenly increases
- Rises again after initially falling
- Reaches the escalation-of-care range
What Changed With the 2022 AAP Guideline?
The 2022 guideline replaced the AAP’s 2004 framework.
Major changes include:
- Slightly higher phototherapy thresholds in many circumstances
- Separate treatment curves based on gestational age
- Explicit neurotoxicity-risk adjustment
- Universal objective bilirubin measurement before discharge
- Clear TcB-to-TSB confirmation rules
- Follow-up based on distance from the phototherapy threshold
- More detailed rebound guidance
- A formal escalation-of-care threshold
- Updated exchange-transfusion guidance
- Greater emphasis on G6PD deficiency and hemolysis
The older Bhutani “risk-zone” nomogram is no longer the system used to determine postdischarge follow-up under the 2022 guideline.
What Does “Distance From the Phototherapy Threshold” Mean?
Suppose the baby’s bilirubin is:
10 mg/dL
and the applicable phototherapy threshold at that moment is:
17 mg/dL
The baby is:
7 mg/dL below the treatment threshold.
Now imagine another baby whose bilirubin is:
16.5 mg/dL
with the same 17 mg/dL threshold.
That baby is only:
0.5 mg/dL below the treatment threshold.
Those babies should not necessarily receive the same follow-up plan.
The closer the bilirubin is to the threshold, the greater the chance that it may cross the treatment line after discharge.
That is the logic behind the AAP’s current Δ-to-threshold approach.
When Is the Δ-to-Threshold Follow-Up System Used?
The AAP’s Figure 7 follow-up system applies to babies who:
- Are at least 12 hours old
- Are being considered for discharge
- Have not already received phototherapy before discharge
The clinician calculates the difference between:
the bilirubin measurement closest to discharge
and:
the phototherapy threshold at that exact age
The follow-up interval is then selected based on that gap along with:
- Feeding
- Weight trajectory
- Gestational age
- Other risk factors
- Family support
- Overall newborn health
A different approach is used for babies who have already received phototherapy because they require evaluation for rebound hyperbilirubinemia.
What If a Baby Is Discharged Very Early?
If a newborn is discharged before 12 hours of age, the AAP states that there is not enough evidence to apply the usual predischarge Δ-to-threshold algorithm.
Those babies should have another bilirubin measurement between 24 and 48 hours after birth.
What Is Intensive Phototherapy?
Phototherapy changes bilirubin into forms the body can more easily eliminate.
But simply putting a light near a baby does not necessarily provide intensive phototherapy.
The effectiveness depends on:
- Wavelength
- Irradiance
- Distance and configuration of the device
- Amount of skin exposed
- Whether treatment is interrupted
- Whether the device is functioning properly
The AAP’s 2024 technical report describes effective intensive phototherapy as blue-to-green LED light generally in the 460–490 nm wavelength range, with an irradiance of at least about 30 µW/cm²/nm for term infants and exposure of as much body surface as possible.
The report emphasizes that effective phototherapy should produce a measurable bilirubin response.
Why the Quality of the Lights Matters
Two babies can both be charted as receiving “phototherapy” while receiving very different effective doses of light.
Important factors include:
- Light source
- Device configuration
- Irradiance
- Skin exposure
- Distance from the device
- Interruptions
- Device maintenance
The AAP recommends that hospitals have systems to verify that phototherapy equipment is delivering appropriate irradiance.
Visual brightness is not an adequate way to judge a phototherapy unit’s therapeutic output.
How Quickly Should Bilirubin Be Rechecked After Phototherapy Starts?
For a hospitalized newborn, the AAP recommends obtaining a TSB within 12 hours after starting phototherapy.
The exact timing and frequency of additional tests should depend on:
- Baby’s age
- Bilirubin level
- How quickly it is changing
- Neurotoxicity risk factors
- Cause of the jaundice
- Response to treatment
A baby whose bilirubin is rapidly rising despite intensive treatment may need testing much sooner and more frequently than a stable baby responding normally.
What Should Happen if Phototherapy Is Working?
The TSB should generally begin to decline.
The 2024 AAP technical report notes that with properly administered effective phototherapy in a baby without ongoing hemolysis, the bilirubin should generally decrease within the first 4–6 hours.
Failure to fall—or continued rapid increase—can raise concern for:
- Inadequate phototherapy delivery
- Hemolysis
- Another ongoing source of bilirubin production
- Need for escalation
Feeding Is Part of Jaundice Management
Newborns need adequate intake to help eliminate bilirubin through stool.
Poor intake can contribute to worsening jaundice.
Monitoring may include:
- Feeding frequency
- Latch and milk transfer
- Formula intake when applicable
- Weight loss
- Urine output
- Stool frequency
- Hydration
The goal is not to automatically stop breastfeeding.
The AAP supports breastfeeding and appropriate lactation assistance.
Supplementation may be appropriate in selected cases when intake is inadequate, weight loss is excessive, dehydration is present, or another clinical reason exists.
When Can Phototherapy Be Stopped?
Stopping phototherapy is not based solely on the baby’s skin appearing less yellow.
Under the 2022 AAP guideline, discontinuing phototherapy is an option when the TSB has fallen at least 2 mg/dL below the hour-specific phototherapy threshold that applied when treatment was started.
A longer treatment period may be appropriate when the baby is at increased risk for rebound, including:
- Gestational age below 38 weeks
- Phototherapy started before 48 hours of age
- Hemolytic disease
The 2024 technical report further emphasizes individualized treatment based on the cause of jaundice, treatment response, and rebound risk.
What Is Rebound Hyperbilirubinemia?
Rebound hyperbilirubinemia means bilirubin returns to the phototherapy treatment threshold after lights are stopped.
Some babies are more likely to rebound than others.
Higher-risk circumstances include:
- Early phototherapy
- Hemolysis
- Positive DAT
- Lower gestational age
- Bilirubin remaining relatively close to the treatment threshold when phototherapy is discontinued
This is why stopping the lights should be accompanied by a follow-up plan.
When Should Bilirubin Be Rechecked After Phototherapy?
The answer depends on rebound risk.
For babies who exceeded the phototherapy threshold during their birth hospitalization and who:
- Started phototherapy before 48 hours of age
- Have a positive DAT
- Have known or suspected hemolysis
the AAP recommends:
TSB 6–12 hours after stopping phototherapy
and:
another bilirubin measurement the following day.
Other babies treated during the birth hospitalization generally should have a bilirubin measurement the day after phototherapy is stopped.
Some infants readmitted later or treated at home may instead have bilirubin testing or clinical follow-up 1–2 days later, depending on risk.
Can Phototherapy Be Done at Home?
Sometimes—but the AAP criteria are deliberately narrow.
Home LED phototherapy may be considered for a baby who has already been discharged and meets all of the following:
- At least 38 weeks’ gestation
- At least 48 hours old
- Clinically well
- Feeding adequately
- No known neurotoxicity risk factors
- No previous phototherapy
- TSB no more than 1 mg/dL above the phototherapy threshold
- Appropriate LED phototherapy device available without delay
- Ability to obtain a TSB every day
Home phototherapy is not simply an alternative for any newborn whose bilirubin is high.
If the baby is clinically unwell, has hemolysis, is premature, cannot obtain daily TSB testing, or otherwise fails the criteria, inpatient treatment may be more appropriate.
What Is the Escalation-of-Care Threshold?
This is one of the most important additions to the 2022 guideline.
The AAP defines the escalation-of-care threshold as:
2 mg/dL below the applicable exchange-transfusion threshold.
Reaching that level is a medical emergency.
The purpose is to begin intensive intervention before the baby actually reaches the exchange-transfusion line.
What Should Happen During Escalation of Care?
When TSB reaches or exceeds the escalation-of-care threshold, the AAP recommends urgent management.
That can include:
- Emergent intensive phototherapy
- IV hydration
- Neonatology involvement
- Total and direct bilirubin
- Complete blood count
- Serum albumin
- Serum chemistries
- Blood type and crossmatch
- Preparation for possible exchange transfusion
TSB should be measured at least every two hours during the escalation-of-care period.
If the hospital cannot perform an emergency exchange transfusion, the AAP recommends urgent consultation and transfer to a NICU capable of doing so.
When feasible, intensive phototherapy and IV hydration should continue during transfer.
Exchange Transfusion Should Not Begin Only After Everything Else Has Failed
A baby should be prepared for exchange transfusion before the situation becomes irreversible.
The AAP recommends an urgent exchange transfusion when:
- TSB is at or above the applicable exchange-transfusion threshold
or
- The baby has intermediate or advanced signs of acute bilirubin encephalopathy
If the bilirubin falls below the exchange threshold while the team is preparing and the baby has no concerning neurological signs, exchange may sometimes be deferred while intensive phototherapy continues and TSB is checked every two hours until it falls below the escalation threshold.
What Is an Exchange Transfusion?
An exchange transfusion gradually removes portions of the baby’s blood and replaces them with compatible donor blood components.
The purpose is to rapidly:
- Reduce circulating bilirubin
- Remove antibody-coated red blood cells in hemolytic disease
- Reduce circulating maternal antibodies
- Prevent or limit bilirubin neurotoxicity
Exchange transfusion is invasive and carries risks.
That is why the treatment strategy aims to identify severe bilirubin elevation before exchange becomes necessary.
But when the indication exists, delaying exchange can carry serious neurological risk.
What About IVIG?
Older protocols sometimes made IVIG sound like a routine step whenever hemolysis was present.
The current AAP guidance is more cautious.
IVIG may be considered for a baby with:
- Isoimmune hemolytic disease
- A positive direct antiglobulin test (DAT)
- TSB at or above the escalation-of-care threshold
But the AAP explicitly states that the effectiveness of IVIG in preventing exchange transfusion is unclear.
Observational studies have also raised concern about an association with necrotizing enterocolitis.
IVIG therefore does not replace:
- Intensive phototherapy
- Frequent bilirubin testing
- Exchange preparation
- Appropriate escalation
What If Bilirubin Suddenly Rises Despite Phototherapy?
That should prompt reassessment.
Questions can include:
- Is the phototherapy actually delivering adequate irradiance?
- Is enough skin exposed?
- Has treatment been interrupted?
- Is hemolysis occurring?
- Does the baby have G6PD deficiency?
- Is there significant bruising or a cephalohematoma?
- Is the baby septic or clinically unstable?
- Is the bilirubin approaching escalation or exchange thresholds?
A rapidly rising bilirubin despite properly delivered intensive phototherapy can be an important warning sign.
What About Babies Born Before 35 Weeks?
This is an important limitation of the AAP guideline.
The 2022 AAP hyperbilirubinemia guideline applies only to newborns at least 35 weeks’ gestation.
It should not simply be extrapolated to a 28-, 30-, or 33-week premature infant.
Preterm babies may be susceptible to bilirubin neurotoxicity at lower bilirubin concentrations.
But there is no equivalent modern AAP evidence-based treatment chart for all infants under 35 weeks.
NICUs commonly use institution-specific protocols, often informed by published expert-consensus recommendations.
One widely cited approach by Maisels, Watchko, Bhutani, and Stevenson provides gestational-age-based operational treatment thresholds for infants under 35 weeks, but the authors explicitly state that those recommendations are consensus-based because high-quality evidence is limited.
Why This Matters in a NICU Case
If a premature baby developed severe jaundice, do not compare the bilirubin values to the AAP ≥35-week chart and assume that answers the question.
Instead determine:
- Gestational age
- Birth weight
- NICU bilirubin protocol in effect
- Risk factors
- Bilirubin trend
- Phototherapy threshold the NICU used
- Exchange threshold the NICU used
- Clinical condition
- Hemolysis
- Albumin
- Sepsis
- Phototherapy delivery
- Response to treatment
The appropriate threshold may be different from that used for a term newborn.
What About Direct or Conjugated Bilirubin?
The brain-toxicity concern discussed in this article primarily involves unconjugated bilirubin.
Elevated direct or conjugated bilirubin points toward a different set of conditions and requires appropriate medical evaluation.
When applying the AAP phototherapy or exchange-transfusion charts, however, the direct bilirubin is not subtracted from the TSB.
In unusual cases where the direct or conjugated fraction exceeds half the total bilirubin, the AAP recommends specialist consultation.
Warning Signs Parents Should Treat Urgently
Parents should contact the child’s medical team promptly when jaundice is worsening or a newborn is not feeding or behaving normally.
AAP parent guidance identifies reasons for urgent evaluation including a baby who:
- Is difficult to wake
- Feeds poorly
- Has a weak suck
- Becomes unusually sleepy
- Appears very weak
- Develops increasingly deep yellow or orange skin
- Has jaundice spreading to the abdomen, arms, or legs
- Appears ill in another way
More advanced bilirubin toxicity can cause high-pitched crying, abnormal muscle tone, or backward arching.
These symptoms require immediate medical attention.
Parents should not attempt to treat significant jaundice by putting a newborn in sunlight.
How Can Kernicterus Still Occur?
Kernicterus has become uncommon, but failures can still occur at several points in the system.
Potential issues can include:
- No objective bilirubin measurement before discharge
- Early jaundice not investigated
- TcB near threshold not confirmed with TSB
- Incorrect gestational-age curve used
- Neurotoxicity risk factors overlooked
- Hemolysis not recognized
- G6PD deficiency missed
- Follow-up scheduled too late
- Family not informed of required follow-up
- Test result not communicated
- Phototherapy delayed
- Inadequate phototherapy dose
- Treatment stopped without appropriate rebound planning
- Bilirubin rising despite therapy without timely escalation
- Delayed transfer to a hospital capable of exchange transfusion
- Neurological warning signs not recognized
The existence of kernicterus does not automatically establish which, if any, of these occurred in a particular case.
The timeline and records have to answer that question.
Kentucky Newborn Transfers for Severe Hyperbilirubinemia
A community hospital may be able to provide phototherapy but may not be equipped to perform an emergency neonatal exchange transfusion or manage severe bilirubin encephalopathy.
In that situation, transfer to a higher-level NICU may become necessary.
UK HealthCare — Kentucky Kids Crew
Kentucky Kids Crew provides 24/7 neonatal and pediatric critical-care transportation to Golisano Children’s at UK and can provide critical-care treatment during interfacility transport.
Norton Children’s — “Just for Kids” Transport Team
Norton Children’s “Just for Kids” Transport Team provides 24/7 specialized neonatal and pediatric ground and helicopter transport. Norton Children’s Hospital operates a Level IV NICU.
For a severe bilirubin case, transport records can help show exactly when escalation occurred.
What Transport Records Matter in a Kernicterus Review?
Look for:
- Time severe bilirubin was identified
- Time escalation-of-care threshold was reached
- Time exchange threshold was reached, if applicable
- Referring physician call
- Receiving physician consultation
- Transfer acceptance
- Transport request
- Transport-team activation
- Team arrival
- Intensive phototherapy before departure
- IV hydration
- Bilirubin levels before departure
- Phototherapy during transport, if applicable
- Departure
- Arrival
- Receiving NICU assessment
- Exchange-transfusion preparation
These events can create a minute-by-minute picture of whether the newborn was moved to definitive treatment in time.
Kentucky Parents Can Request the Medical Records
Kentucky KRS 422.317 provides that, upon a patient’s written request, covered hospitals and healthcare providers must supply a copy of the patient’s medical record without charge for the first copy.
Kentucky KRS 422.355 separately gives a parent or qualifying personal representative access to the medical record of a patient under age 18, subject to applicable federal and state-law exceptions.
For a jaundice or kernicterus investigation, request the baby’s complete newborn/NICU chart rather than only the discharge summary.
What Records Should Parents Request?
Every Bilirubin Result
Request:
- TcB values
- TSB values
- Direct/conjugated bilirubin
- Collection date
- Exact collection time
- Result-release time when available
The baby’s age in hours at each measurement is essential.
Phototherapy Documentation
Request:
- Phototherapy order
- Start time
- Stop time
- Device type
- Intensive versus standard therapy documentation
- Irradiance measurements, if charted
- Nursing flowsheets
- Eye-protection documentation
- Temperature
- Feeding during therapy
- Interruptions
- Bilirubin levels during treatment
If the hospital maintains device-specific irradiance or maintenance records outside the patient chart, those may require a separate request or later legal process.
Hemolysis Workup
Depending on the circumstances, useful records may include:
- Maternal blood type
- Baby’s blood type
- DAT/Coombs result
- Hemoglobin
- Hematocrit
- Reticulocyte count
- Peripheral smear
- G6PD test
- Other testing for red-cell disorders
A positive DAT alone does not tell the entire story, but it can be important when isoimmune hemolysis is suspected.
Feeding and Weight Records
Request:
- Birth weight
- Daily weights
- Percent weight loss
- Breastfeeding documentation
- Lactation consultations
- Formula or expressed-milk supplementation
- Intake records
- Urine output
- Stool output
Poor intake can contribute to worsening hyperbilirubinemia and can affect discharge and follow-up decisions.
Discharge Documentation
Look for:
- Last bilirubin level
- Baby’s age when measured
- Applicable treatment threshold
- Distance below threshold
- Follow-up appointment
- Planned repeat bilirubin
- Written jaundice education
- Pediatrician notified of bilirubin information
- Feeding plan
- Return precautions
The AAP recommends that follow-up information and key bilirubin-risk information be transmitted to the clinician responsible for postdischarge care.
Readmission Records
If the baby returned after discharge, request:
- Emergency-department record
- Repeat bilirubin
- Feeding/weight assessment
- Neurological examination
- Phototherapy
- Escalation records
- Transfer records
- Exchange-transfusion documentation
- Neurology consultation
- Hearing testing
- MRI when performed
The readmission record can reveal how far bilirubin progressed between discharge and return.
Build a Bilirubin Timeline
Use this worksheet to reconstruct the sequence.
Birth date/time:
Gestational age:
Birth weight:
Maternal blood type:
Baby blood type:
DAT: Positive / Negative / Unknown
First visible jaundice:
First TcB:
Value ______ Time ______ Age in hours ______
First TSB:
Value ______ Time ______ Age in hours ______
Applicable phototherapy threshold:
Distance below/above threshold:
Second bilirubin:
Value ______ Time ______
Rate of rise:
Hemolysis suspected: Yes / No / Unknown
G6PD testing:
Phototherapy ordered:
Phototherapy started:
TSB after treatment began:
Phototherapy stopped:
Rebound test:
Discharge bilirubin:
Follow-up ordered for:
Outpatient bilirubin:
Escalation-of-care threshold reached:
Exchange threshold reached:
Transfer requested:
Transport activated:
Transport departed:
Receiving NICU arrival:
Exchange transfusion:
Neurological signs:
MRI/hearing evaluation:
Where information cannot be established from the records, write:
Unknown
rather than guessing.
Why Exact Times Matter
Consider this example:
9:00 a.m. — TSB 15.8
4:00 p.m. — TSB 18.0
11:00 p.m. — TSB 21.4
Simply listing three bilirubin values does not tell the whole story.
A review also needs:
- Gestational age
- Exact age in hours
- Applicable threshold at each time
- Neurotoxicity risk factors
- Whether phototherapy was running
- Quality of phototherapy
- Whether hemolysis was suspected
- Feeding and weight
- Whether the rate of rise was recognized
- When escalation occurred
The medical significance of “21.4” depends on the complete context.
Frequently Asked Questions
Does every jaundiced baby need a blood test?
Every baby covered by the AAP guideline should receive at least one objective bilirubin measurement with either TcB or TSB between 24–48 hours after birth or before earlier discharge.
A blood TSB becomes necessary when TcB reaches the AAP’s confirmation criteria or when treatment decisions need to be made.
Can doctors tell how high bilirubin is by looking at the baby’s skin?
Not reliably enough for treatment decisions.
Visual assessment remains important, but it supplements rather than replaces objective bilirubin testing.
What bilirubin number is dangerous?
There is no universal number.
Risk depends on:
- Gestational age
- Age in hours
- Neurotoxicity risk factors
- Clinical condition
- Treatment response
The correct AAP threshold chart must be used.
Does a 35-week baby automatically use the lower “risk factor” curve?
No.
The AAP already incorporates gestational age into its gestational-age-specific threshold curves.
For a 35- to 37-week infant, the separate curve for additional neurotoxicity risk factors is used when another recognized neurotoxicity factor is present.
Does the AAP still use the old Bhutani risk zones?
Not for the current postdischarge follow-up framework.
The 2022 guideline uses the difference between the bilirubin level and the phototherapy threshold at the baby’s current age.
Is TcB enough to decide whether to start phototherapy?
TSB is the definitive test used to guide phototherapy and escalation decisions.
A near-threshold or high TcB should be confirmed according to AAP criteria.
Does phototherapy always work?
Most appropriately treated babies respond.
A bilirubin that continues to rise despite effective intensive phototherapy deserves reassessment for hemolysis, inadequate light delivery, or another cause and may require escalation.
How often should bilirubin be checked during phototherapy?
For hospitalized infants, the AAP recommends a TSB within 12 hours after treatment begins.
The subsequent interval depends on risk, bilirubin trajectory, age, and clinical circumstances.
During formal escalation of care, TSB should be checked at least every two hours.
Is home phototherapy always an option?
No.
The AAP permits it only for carefully selected infants who meet strict criteria, including gestational age of at least 38 weeks, age of at least 48 hours, good clinical status, adequate feeding, absence of neurotoxicity risks, and daily TSB access.
Is the exchange threshold the point when doctors should first become worried?
No.
The AAP intentionally created an escalation threshold 2 mg/dL below the exchange-transfusion threshold so intensive measures can begin before the exchange line is crossed.
Is IVIG required when the DAT is positive?
No.
The AAP says IVIG may be used in selected DAT-positive isoimmune hemolysis cases when bilirubin reaches the escalation-of-care threshold.
Its benefit is uncertain, and it does not replace intensive phototherapy and exchange-transfusion preparation.
Does the AAP 2022 chart apply to a 32-week premature baby?
No.
The AAP guideline applies to babies 35 weeks and older.
NICUs use separate protocols for younger premature infants, often informed by consensus recommendations because evidence is more limited.
Can timely phototherapy prevent kernicterus?
Timely, appropriately delivered intensive phototherapy is a central tool for preventing dangerous bilirubin accumulation.
In severe cases, however, phototherapy alone may not be enough, which is why the AAP includes escalation-of-care and exchange-transfusion pathways.
Does kernicterus automatically prove malpractice?
No.
Kernicterus is a serious permanent bilirubin-related brain injury, but determining whether medical negligence caused it requires reconstructing the entire sequence.
Questions can include:
- Was bilirubin measured appropriately?
- Was the correct threshold used?
- Were risk factors identified?
- Was follow-up appropriate?
- Was phototherapy timely and effective?
- Was hemolysis investigated?
- Was escalation timely?
- Was transfer delayed?
- Were neurological signs recognized?
Qualified medical experts ordinarily must evaluate those questions in context.
Questions About Severe Jaundice or Kernicterus in Kentucky?
If your child developed severe hyperbilirubinemia, acute bilirubin encephalopathy, or kernicterus and you have questions about whether the condition was recognized and treated promptly, Morrin Law Office can help identify the records needed to reconstruct the timeline.
A review may focus on:
screening → bilirubin trend → treatment threshold → phototherapy → response → rebound → escalation → transport → exchange transfusion → neurological outcome
The goal is not to assume that every severe jaundice case resulted from negligence.
It is to determine what the specific medical records and qualified expert review support.
Call Morrin Law Office for a free consultation
859-358-0300
214 W Main St., Richmond, KY 40475
Sources and Public Resources
- American Academy of Pediatrics — Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation (2022). Current AAP guideline governing bilirubin screening, phototherapy thresholds, treatment, rebound monitoring, escalation of care, exchange transfusion, and follow-up for newborns at least 35 weeks’ gestation.
AAP — 2022 Hyperbilirubinemia Clinical Practice Guideline - American Academy of Pediatrics — Hyperbilirubinemia Clinical Guidance. AAP’s current resource page states that the 2022 guideline remains valid for practice through August 2027 and provides treatment graphs, quality-improvement resources, and family materials.
AAP — Hyperbilirubinemia Clinical Guidance and Tools - American Academy of Pediatrics — Frequently Asked Questions About the 2022 AAP Guideline (updated July 17, 2025). Clarifies gestational-age risk, DAT and albumin testing, rebound decisions, G6PD issues, and implementation of the guideline.
AAP — Hyperbilirubinemia Guideline FAQ - American Academy of Pediatrics — Phototherapy to Prevent Severe Neonatal Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation: Technical Report (2024). Current technical report detailing effective phototherapy wavelength, irradiance, skin exposure, monitoring, treatment response, G6PD evaluation, and rebound considerations.
AAP — 2024 Phototherapy Technical Report - American Academy of Pediatrics — Monitoring Neonatal Bilirubin After Discharge. Reviews implementation of the 2022 guideline, universal predischarge screening, Δ-to-threshold follow-up, rebound monitoring, feeding assessment, and escalation of care.
AAP Pediatrics in Review — Monitoring Neonatal Bilirubin After Discharge - American Academy of Pediatrics / HealthyChildren.org — Jaundice in Newborns. Parent-facing guidance on warning signs, bilirubin testing, phototherapy, severe hyperbilirubinemia, and when families should seek medical attention.
HealthyChildren.org — Jaundice in Newborns - Maisels, Watchko, Bhutani & Stevenson — An Approach to the Management of Hyperbilirubinemia in the Preterm Infant Less Than 35 Weeks of Gestation (Journal of Perinatology, 2012). Widely cited consensus-based approach for premature infants not covered by the AAP ≥35-week guideline; the authors emphasize that evidence for this population is limited.
PubMed — Hyperbilirubinemia in Preterm Infants Under 35 Weeks - Kentucky Revised Statutes — KRS 422.317. Provides for a patient’s first requested copy of the medical record without charge upon written request to covered Kentucky healthcare providers and hospitals.
Kentucky Legislature — KRS 422.317 - Kentucky Revised Statutes — KRS 422.355. Provides parents and qualifying personal representatives access to the health information in the medical record of a patient under age 18, subject to applicable federal and state-law exceptions.
Kentucky Legislature — KRS 422.355 - UK HealthCare — Kentucky Kids Crew. Provides 24/7 neonatal and pediatric interfacility critical-care transportation by ground and air to Golisano Children’s at UK.
UK HealthCare — Kentucky Kids Crew - Norton Children’s — “Just for Kids” Transport Team. Provides 24/7 specialized neonatal and pediatric interfacility transport by ground and helicopter.
Norton Children’s — Just for Kids Transport Team
Disclaimer
This page provides general educational information about newborn jaundice, hyperbilirubinemia, acute bilirubin encephalopathy, and kernicterus.
It is not medical advice and should not be used to interpret a current newborn bilirubin result or decide whether a baby needs phototherapy, transfer, IVIG, or exchange transfusion.
A newborn who is difficult to wake, feeding poorly, unusually weak, increasingly jaundiced, or otherwise ill needs prompt medical evaluation.
This page is also not individualized legal advice. A high bilirubin result, phototherapy, readmission, exchange transfusion, acute bilirubin encephalopathy, or diagnosis of kernicterus does not by itself establish medical negligence.
The significance of a jaundice case depends on gestational age, the baby’s age in hours, bilirubin trend, neurotoxicity risk factors, feeding, hemolysis, treatment quality, follow-up, transport, medical records, applicable clinical guidance, and other case-specific facts.
0 Comments